New York is becoming a cultural center for young women trying to disrupt the male-dominated industries of design engineering and sex toys.
NYS Entity Status
NYS Filing Date
JULY 19, 2013
NYS DOS ID#
NYS Entity Type
DOMESTIC LIMITED LIABILITY COMPANY
2013 - LIQUITERIA SECOND AVE LLC
AROUND THE WEB
- Women of Sex Tech, Unite
By ANNA NORTH - Friday Aug 18, 2017
- The Top 10 Moments of New York Fashion Week
By THE NEW YORK TIMES - Friday Sep 15, 2017
Highlights from the shows, including a celebrity-packed front row at Calvin Klein and a trek to Bedford Hills, N.Y., to see Ralph Lauren’s vintage cars.
- Dodgers, Astros leading the pack heading into second half
By Associated Press - Thursday Jul 13, 2017
The Nationals have Bryce Harper anchoring one of baseball’s best lineups, and a glaring hole at the back of their bullpen.The Dodgers’ plus-163 run differential is the best in National League history at the All-Star break, according to Stats LLC.Another starting pitcher could help the Cubs, so expect top executive Theo Epstein and company to be working the phones all the way to the non-waiver trade deadline July 31.The Astros, Brewers, Rockies and Yankees also could be on the lookout for rotation help.Some possibilities include White Sox left-hander Jose Quintana, A’s right-hander Sonny Gray and the Tigers’ Justin Verlander.
- Trump’s Tough Talk on North Korea Puts Japan’s Leader in Delicate Spot
By JONATHAN SOBLE - Friday Aug 11, 2017
North Korea’s accelerating military advances — and President Trump’s volatile response — could complicate Japan’s close alliance with the United States.
- Ian Poulter aims for nothing short of 1st at Royal Birkdale - this time
By Alistair Tait - Tuesday Jul 4, 2017
WOBURN, England – Ian Poulter heads back to Royal Birkdale and the Open Championship looking to better his finish the last time the Open (...)
- IFM Gets $300M Bristol Buyout, Plans Second Strike With New Spinout
By Ben Fidler - Thursday Aug 3, 2017
Bristol-Myers Squibb this afternoon is acquiring a young startup, IFM Therapeutics, in an unusual deal that will also see the big drugmaker get a chance to own rights in a new company the biotech is spinning out as well. New York-based Bristol (NYSE: BMY) will pay $300 million up front for IFM, which will give […]